Nicholas C. D’Amato

Author

Nicholas C. D’Amato

University of Colorado Anschutz Medical Campus

Also Known As

Nicholas C D'Amato, Nicholas C D’Amato, Nicholas C. D'Amato, Nicholas C. D’Amato, Nicholas D'Amato, Nicholas D’Amato

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

University of Colorado Anschutz Medical Campus Duke Medical Center Duke University

About

Nicholas C. D’Amato is an author at University of Colorado Anschutz Medical Campus specializing in medicine, tumor biology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	529
2	Cell Biology	3	3	529
3	Cancer Cell Biology	2	2	504
4	Pharmacology	1	1	211
5	Cancer Genetics	1	1	293

Nicholas C. D’Amato

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide Dawn R. Cochrane, Sebastián Bernales, Britta M. Jacobsen, Breast Cancer Research	2014	391
A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer Nicholas C. D’Amato, Thomas J. Rogers, Melita A. Gordon, Cancer Research Breast OncologyCell DeathCancer BiologyMammary Gland DevelopmentTumor Biology	2015	293
Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide <i>In Vivo</i> Valerie N. Barton, Nicholas C. D’Amato, Melita A. Gordon, Molecular Cancer Therapeutics Androgen ReceptorBreast OncologyCancer BiologyTumor BiologyOncology	2015	211
Cooperative Dynamics of AR and ER Activity in Breast Cancer Nicholas C. D’Amato, Melita A. Gordon, Beatrice Babbs, Molecular Cancer Research	2016	136
Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer Valerie N. Barton, Jessica L. Christenson, Melita A. Gordon, Cancer Research	2017	85
Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer Melita A. Gordon, Nicholas C. D’Amato, Haihua Gu, Molecular Cancer Therapeutics	2017	59
CpG Island Tumor Suppressor Promoter Methylation in Non-BRCA-Associated Early Mammary Carcinogenesis Shauna N. Vasilatos, Gloria Broadwater, William T. Barry, Cancer Epidemiology Biomarkers & Prevention	2009	51
Evidence for Phenotypic Plasticity in Aggressive Triple-Negative Breast Cancer: Human Biology Is Recapitulated by a Novel Model System Nicholas C. D’Amato, Julie H. Ostrander, Michelle Bowie, PLoS ONE Epithelial-mesenchymal TransitionLineage PlasticityBreast OncologyTumor HeterogeneitySingle Dkat Cells	2012	25
Which Comes First, The Root or The Crack? Nicholas C. D’Amato, T. Davis Sydnor, Michael Knee, Arboriculture & Urban Forestry Comes FirstBotanyUrban ForestryForestryDynamic Crack Propagation	2002	22
<i>ESR1</i> Promoter Hypermethylation Does Not Predict Atypia in RPFNA nor Persistent Atypia after 12 Months Tamoxifen Chemoprevention Joseph C. Baker, Julie H. Ostrander, Siya Lem, Cancer Epidemiology Biomarkers & Prevention	2008	12

Page 1